GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (BSP:G1LP34) » Definitions » Return-on-Tangible-Equity

Galapagos NV (BSP:G1LP34) Return-on-Tangible-Equity : -23.36% (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Galapagos NV Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Galapagos NV's annualized net income for the quarter that ended in Mar. 2025 was R$-3,820 Mil. Galapagos NV's average shareholder tangible equity for the quarter that ended in Mar. 2025 was R$16,353 Mil. Therefore, Galapagos NV's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 was -23.36%.

The historical rank and industry rank for Galapagos NV's Return-on-Tangible-Equity or its related term are showing as below:

BSP:G1LP34' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -41.73   Med: -3.31   Max: 9.64
Current: -6.44

During the past 13 years, Galapagos NV's highest Return-on-Tangible-Equity was 9.64%. The lowest was -41.73%. And the median was -3.31%.

BSP:G1LP34's Return-on-Tangible-Equity is ranked better than
74.18% of 1251 companies
in the Biotechnology industry
Industry Median: -43.82 vs BSP:G1LP34: -6.44

Galapagos NV Return-on-Tangible-Equity Historical Data

The historical data trend for Galapagos NV's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Return-on-Tangible-Equity Chart

Galapagos NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.05 -4.02 -8.26 8.47 3.06

Galapagos NV Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.71 1.39 -7.87 3.91 -23.36

Competitive Comparison of Galapagos NV's Return-on-Tangible-Equity

For the Biotechnology subindustry, Galapagos NV's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Return-on-Tangible-Equity falls into.


;
;

Galapagos NV Return-on-Tangible-Equity Calculation

Galapagos NV's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=473.271/( (13882.426+17006.567 )/ 2 )
=473.271/15444.4965
=3.06 %

Galapagos NV's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=-3819.72/( (17006.567+15698.946)/ 2 )
=-3819.72/16352.7565
=-23.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2025) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Galapagos NV  (BSP:G1LP34) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Galapagos NV Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Galapagos NV Headlines

No Headlines